title: Tacrolimus reduces staphylococcal colonization on the skin in Korean atopic dermatitis patients.
abstract: It is well known that topical tacrolimus is safe and effective in the treatment of atopic dermatitis (AD) patients. Tacrolimus is primarily an immunosuppressive agent without any antistaphylococcal effects. Thus colonization of Staphylococcus aureus on the skin of patients treated with this agent might be increased. The purpose of this study was to determine the effect of tacrolimus on S. aureus colonization in patients with AD and to compare the results with clinical severity and skin barrier function. We enrolled 65 patients with moderate to severe AD. They were treated with 0.03% tacrolimus ointment twice daily for 4 weeks. Clinical severity was assessed by the eczema area and severity index (EASI). S. aureus colonization was measured by the tape method. Skin barrier function was checked by measuring transepidermal water loss (TEWL). Evaluations were performed at weeks 0 (baseline), 1, 2 and 4. The results were compared and statistical analysis was performed. S. aureus colonization was significantly decreased with tacrolimus treatment at week 1 compared with baseline. However, there were no differences among weeks 1, 2 and 4. EASI and TEWL showed a decreasing tendency in a time-dependent fashion. The correlations between data were variable.
authors.affiliation: Department of Dermatology, College of Medicine, Hallym University, Seoul, Korea. medlee07@yahoo.co.kr
authors.forename: C W
authors.initials: CW
authors.lastname: Park
authors.forename: B H
authors.initials: BH
authors.lastname: Lee
authors.forename: C H
authors.initials: CH
authors.lastname: Lee
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D015824:Blood-Air Barrier; D002648:Child; D002675:Child, Preschool; D015169:Colony Count, Microbial; D003876:Dermatitis, Atopic / Q000382:microbiology*; D004485:Eczema / Q000382:microbiology; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D012621:Seasons; D012867:Skin / Q000382:microbiology*; D013210:Staphylococcus / Q000254:growth & development*; D016559:Tacrolimus / Q000008:administration & dosage / Q000494:pharmacology*; D014870:Water Loss, Insensible / Q000187:drug effects
chemical_list: D007166:Immunosuppressive Agents; D016559:Tacrolimus